Brokerages predict that Mirum Pharmaceuticals (NASDAQ:MIRM) will post ($0.85) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Mirum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.83) and the lowest is ($0.86). The business is expected to report its next earnings results on Wednesday, February 5th.
According to Zacks, analysts expect that Mirum Pharmaceuticals will report full-year earnings of ($4.84) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will report earnings of ($3.36) per share, with EPS estimates ranging from ($3.49) to ($3.22). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Mirum Pharmaceuticals.
Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.84) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.25).
Shares of NASDAQ:MIRM opened at $9.57 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.85 and a current ratio of 11.85. The stock’s 50-day simple moving average is $7.55. Mirum Pharmaceuticals has a 1 year low of $6.51 and a 1 year high of $15.50.
Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at about $42,000. State Street Corp purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth about $197,000. Dean Capital Investments Management LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth about $457,000. Finally, Millennium Management LLC bought a new position in Mirum Pharmaceuticals during the 3rd quarter valued at about $1,261,000. 71.72% of the stock is owned by institutional investors and hedge funds.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Further Reading: When can a hold rating present a buying opportunity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.